MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive gain
-$17,494K
(-264.46%↓ Y/Y)
Unrealized gain (loss) on
short-term investments
$1K
(-97.92%↓ Y/Y)
CINVANTI
$23,955K
ZYNRELEF
$9,313K
Aponvie
$3,034K
SUSTOL
$1,911K
Net gain
-$17,495K
(-260.87%↓ Y/Y)
Net product sales
$38,213K
(16.47%↑ Y/Y)
Loss on debt
extinguishment
-$11,339K
Gain from operations
-$4,093K
(8.19%↑ Y/Y)
Other expense, net
-$2,063K
(-428.97%↓ Y/Y)
Gross profit
$26,299K
(12.62%↑ Y/Y)
Cost of product sales
$11,914K
(25.97%↑ Y/Y)
Total operating
expenses
$30,392K
(9.28%↑ Y/Y)
General and
administrative
$13,980K
(12.99%↑ Y/Y)
Sales and marketing
$12,942K
(17.95%↑ Y/Y)
Research and development
$3,470K
(-22.28%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
HERON THERAPEUTICS, INC. DE (HRTX)
HERON THERAPEUTICS, INC. DE (HRTX)